Adolescent girls and young women can and will use HIV prevention products with consistency, according to interim results of a study being conducted in Africa of two different methods: daily use of the antiretroviral (ARV) tablet Truvada® as oral pre-exposure prophylaxis (PrEP) and the monthly dapivirine vaginal ring, a new HIV prevention product currently under regulatory review in several countries. This was not been the case in previous trials of either approach.
